BEIGENE LTD-ADR (ONC) Stock Price, Quote, News and Overview
NASDAQ:ONC - Nasdaq - US07725L1026 - ADR - Currency: USD
ONC Quote, Performance and Key Statistics
NASDAQ:ONC (2/20/2025, 1:37:06 PM)
244.195
+7.5 (+3.17%)
The current stock price of ONC is 244.195 USD. In the past month the price increased by 8.23%.
ONC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.76 | 353.30B | ||
| AMGN | AMGEN INC | 14.89 | 158.52B | ||
| GILD | GILEAD SCIENCES INC | 23.7 | 136.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1654.45 | 123.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.22 | 75.93B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.21B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.28B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.19B | ||
| NTRA | NATERA INC | N/A | 22.00B | ||
| BIIB | BIOGEN INC | 8.34 | 20.01B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.37 | 16.64B |
Related stock screener links
About ONC
Company Profile
Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The firm has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The firm has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. The company also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Company Info
BEIGENE LTD-ADR
c/o Mourant Governance Services (Cayman), 94 Solaris Avenue, Camana Bay
George Town BEIJING KY
Employees: 10000
Company Website: https://www.beigene.com/
Investor Relations: https://ir.beigene.com
Phone: 13459494123
BEIGENE LTD-ADR / ONC FAQ
What is the stock price of BEIGENE LTD-ADR today?
The current stock price of ONC is 244.195 USD. The price increased by 3.17% in the last trading session.
What is the ticker symbol for BEIGENE LTD-ADR stock?
The exchange symbol of BEIGENE LTD-ADR is ONC and it is listed on the Nasdaq exchange.
On which exchange is ONC stock listed?
ONC stock is listed on the Nasdaq exchange.
What is BEIGENE LTD-ADR worth?
BEIGENE LTD-ADR (ONC) has a market capitalization of 26.06B USD. This makes ONC a Large Cap stock.
How many employees does BEIGENE LTD-ADR have?
BEIGENE LTD-ADR (ONC) currently has 10000 employees.
What are the support and resistance levels for BEIGENE LTD-ADR (ONC) stock?
BEIGENE LTD-ADR (ONC) has a support level at 227.54. Check the full technical report for a detailed analysis of ONC support and resistance levels.
Is BEIGENE LTD-ADR (ONC) expected to grow?
The Revenue of BEIGENE LTD-ADR (ONC) is expected to grow by 54.2% in the next year. Check the estimates tab for more information on the ONC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BEIGENE LTD-ADR (ONC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ONC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ONC, evaluating the profitability, health, valuation and growth aspects
- BEIGENE LTD-ADR (ONC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BEIGENE LTD-ADR (ONC) Sales and EPS estimates to see what analysts future expectations are.
- BEIGENE LTD-ADR (ONC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BEIGENE LTD-ADR (ONC) Insider and Institutional Ownership to learn about the owners and their transactions.
- BEIGENE LTD-ADR (ONC) Stock Chart to make your own analysis
- BEIGENE LTD-ADR (ONC) Latest news and press-releases to stay up to date.
Does BEIGENE LTD-ADR (ONC) stock pay dividends?
ONC does not pay a dividend.
When does BEIGENE LTD-ADR (ONC) report earnings?
BEIGENE LTD-ADR (ONC) will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of BEIGENE LTD-ADR (ONC)?
BEIGENE LTD-ADR (ONC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-49.65).
What is the Short Interest ratio of BEIGENE LTD-ADR (ONC) stock?
The outstanding short interest for BEIGENE LTD-ADR (ONC) is 17.58% of its float. Check the ownership tab for more information on the ONC short interest.
ONC Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ONC.
ONC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ONC. Both the profitability and financial health of ONC have multiple concerns.
ONC Financial Highlights
Over the last trailing twelve months ONC reported a non-GAAP Earnings per Share(EPS) of -49.65. The EPS decreased by -457.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.97% | ||
| ROE | -26.99% | ||
| Debt/Equity | 0.31 |
ONC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ONC. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 58.94% and a revenue growth 54.2% for ONC